Enliven Therapeutics Appoints Kristine Ball to Board of Directors

PUBT · 2d ago
Enliven Therapeutics Appoints Kristine Ball to Board of Directors
  • Enliven Therapeutics appointed Kristine Ball to its board, effective immediately, on Oct. 14, 2026.
  • Ball brings more than 20 years of executive experience, including CEO roles at Antiva Biosciences and Soteria Biotherapeutics.
  • Her background includes serving as Relypsa's chief financial officer, helping guide its transition from clinical development to commercial operations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610141630PR_NEWS_USPR_____LA72291) on October 14, 2026, and is solely responsible for the information contained therein.